Short answer
NEOGENOMICS INC (NEO) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $209M (up 11.4% year over year) with net income of −$8M.
Q3 2026 key financials · XBRL
- Revenue
- $209M
- +11.4% YoY · +3.8% QoQ
- Net income
- −$8M
- +72.2% YoY · −437.2% QoQ
- Operating margin
- -3.8%
- Gross margin
- 46.2%
Source: XBRL data from the NEOGENOMICS INC (NEO) Q3 2026 10-Q on SEC EDGAR. USD.
NEOGENOMICS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $209.3M, up 11.4% YoY from $187.8M, driven by higher test volume and average unit pricing
- Gross margin 46.2% vs 42.8% YoY, with gross profit $96.6M vs $80.4M
- Single operating segment, no segment-level performance comparison disclosed
- Cash $139.3M vs $164.1M year-end; operating cash flow $2.9M vs $3.9M YoY
- Capital deployment: $306.3M convertible-note issuance, $262.9M note repayment, $25.0M share repurchases
- Outlook: $35.0M 2026 capital expenditures; macro clinical-trial trends, tariffs and supply-chain uncertainty as headwinds
Risk Factors
- No material changes disclosed from the December 31, 2025 Form 10-K
- Carried-forward risks include those described in the 2025 Annual Report, with no quarterly updates identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NEOGENOMICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.